Bhoj, Vijay G. creator Autor Kaminski, María Zhao, Huiwu Jackson, Kyle Wang, Wei Liu, Chengyang Montgomery, Robert A. Ali, Nicole Mangiola, Massimo Spitzer, Thomas R. Safa, Kassem text pe monographic spa eng

print

páginas: 2117-2125 HLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination (desensitization) have had inconsistent efficacy and have often failed to produce sustained reductions in anti-HLA antibodies in patients with the highest level of sensitization (calculated panel-reactive antibody score, ≥99.9%). We now report the results for the safety run-in cohort of a multicenter phase 1 clinical study evaluating the safety and efficacy of combined CD19-targeted and B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T cells in eliminating the cellular sources of preformed anti-HLA antibodies (ClinicalTrials.gov number, NCT06056102). Kidney transplantation was performed in two highly sensitized candidates after desensitization with the use of dual CAR T-cell therapy. ENFERMEDAD RENAL CRÓNICA TRASPLANTE DE RIÑÓN CIRUGÍA GENERAL CÉLULAS T TRASPLANTE Massachusetts NEJM Group NEJM011 0028-4793 ESSALUD BMG 20260820161112.0 ESSALUD